Document is current

Article History

Accepted: 1 December 2024

First Online: 9 December 2024

Declarations

:

: Approval was obtained from the NCI Adult Central Institutional Review Board – Early Phase Emphasis. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

: JJ: Consultant or advisory role: AstraZeneca, Cardinal Health Research funding or contracted research: Roche/ Genentech, AztraZeneca JS: Consultant or advisory role: Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Beigene, BMS, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson and Johnson, Jazz Pharmaceuticals, Leap, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics Stock options- Triumvira Immunologics Research funding or contracted research: Abbvie, Amgen, Apollo Therapeutics, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/ Genentech HJL: Stock options – Fulgent, 3 T Bioscience, Breakbio; Advisory Board-BMS, Adagene, 3 T Bioscience, Merck, Merck KG, Abbvie, Bayer; Research funding or contracted research: UM1CA186717, P30CA014089. MC: Honoraria-Amgen, AstraZeneca, Astellas, Bayer, Basilea, Bristol-Myers Squibb, Eisai, Exelixis, I-Mab, Ipsen, Incyte, Genetech/Roche, Natera, Pfizer, Seattle Genetics, Taiho, Tempus, QED; Employment – Replimune.